# Phase I Single-blind Clinical Trial to Evaluate the Safety and Local Immune Activation of a Toll-like Receptor 5 Agonist (FLAMOD) Administered by Aerosol

> **NCT06681402** · PHASE1 · COMPLETED · sponsor: **Institut National de la Santé Et de la Recherche Médicale, France** · enrollment: 46 (actual)

## Conditions studied

- Pneumonia

## Interventions

- **DRUG:** FLAMOD
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06681402
- **Lead sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-14
- **Primary completion:** 2026-04-17
- **Final completion:** 2026-04-17
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06681402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06681402, "Phase I Single-blind Clinical Trial to Evaluate the Safety and Local Immune Activation of a Toll-like Receptor 5 Agonist (FLAMOD) Administered by Aerosol". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06681402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*